论文部分内容阅读
目的 比较两组不同新辅助化疗方案治疗乳腺癌的疗效及毒性反应。方法 用FEC、ET化疗方案治疗Ⅱ、Ⅲ期乳腺癌 48例 ,3～ 4周为 1个周期。所有患者完成 2个周期新辅助化疗后评价疗效。FEC方案 :氟尿嘧啶 (5 Fu) 5 0 0mg/m2 ,d1,8,持续 4h静脉滴注 ;表阿霉素 (EPI) 5 0mg/m2 ,d1,静脉注射 ;环磷酰胺 (CTX) 5 0 0mg/m2 ,d1,8,静脉注射。ET方案 :EPI 6 0mg/m2 ,d1,静脉注射 ;紫杉醇(TAX) 15 0mg/m2 ,d2 ,持续 3h静脉滴注。结果 FEC组的总有效率为 5 0 .0 % (12 / 2 4) ,其中临床完全缓解 (cCR) 1例 ,部分缓解 (PR) 11例 ,无变化 (NC) 12例 ;ET组的总有效率为 79.2 % (19/ 2 4) ,其中cCR1例 ,PR 18例 ,NC 5例。两组均无病理完全缓解及进展者 ,Ⅱ期疗效高于Ⅲ期。 48例患者新辅助化疗前患侧腋窝均可触及肿大淋巴结 ,化疗 2个周期后 ,FEC组有 12例 (5 0 .0 % )未触及肿大淋巴结 ,ET组有 16例 (6 6 .7% )未触及肿大淋巴结。两组白细胞下降、胃肠道反应相似 ;ET组脱发程度较重 ,并伴有关节肌肉疼痛、神经毒性以及面色潮红等毒性反应。结论 两组新辅助化疗方案对乳腺癌治疗均有效 ,毒性反应均可耐受。ET组疗效及毒性反应均高于FEC组。
Objective To compare the efficacy and toxicity of two different neoadjuvant chemotherapy regimens in the treatment of breast cancer. Methods Forty-eight cases of stage Ⅱ and Ⅲ breast cancer were treated with FEC and ET chemotherapy regimens. One cycle was observed in 3 to 4 weeks. All patients completed two cycles of neoadjuvant chemotherapy to evaluate the efficacy. FEC regimen: fluorouracil (5 Fu) 500 mg / m2, d1,8 for 4 h, intravenous infusion of epirubicin (EPI) 50 mg / m2 d1 iv injection CTX 500 mg / m2, d1,8, intravenous injection. ET program: EPI 6 0mg / m2, d1, intravenous injection; paclitaxel (TAX) 15 0mg / m2, d2, continuous 3h intravenous infusion. Results The total effective rate was 50.0% (12/14) in FEC group, including 1 case of complete clinical remission (cCR), 11 cases of partial remission (PR) and 12 cases of no change (NC) The effective rate was 79.2% (19/2 4), including 1 case of cCR, 18 cases of PR and 5 cases of NC. No pathological complete remission and progression in both groups, Ⅱ period effect is higher than Ⅲ period. In 48 patients, the enlarged axillary lymph nodes were found in the affected side of axillary neoplasm before neoadjuvant chemotherapy. After 2 cycles of chemotherapy, 12 cases (50.0%) in the FEC group did not touch the swollen lymph nodes. There were 16 cases in the ET group (66 cases). 7%) did not touch the enlarged lymph nodes. Two groups of leukopenia, gastrointestinal reactions similar; ET group heavier hair loss, accompanied by joint muscle pain, neurotoxicity and flushing and other toxic reactions. Conclusion Both neoadjuvant chemotherapy regimens are effective in the treatment of breast cancer, and the toxicity can be tolerated. ET group efficacy and toxicity were higher than the FEC group.